Table 1: Principal Studies Investigating the Role of Haemodynamic Support in Patients Undergoing Catheter Ablation Ventricular Tachycardia.
| Study | Treatment Group, n | Control Group, n | Age, years | LVEF | Acute Procedural Success, % | Type of Haemodynamic Support | VT Recurrence, % | Mortality/Transplant, % | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
| Carbucicchio et al., 2009[23] | 19 | No control group | 61 ± 6 | NA | 68 | CPS | 50 | 21 | Mean: 42 months |
| Abuissa et al., 2010[26] | 3 | No control group | 55 (mean) | NA | 100 | Impella | 0 | 0 | Mean: 7 months |
| Miller et al., 2011[14] | 10 | IABP: 6 No MHS: 7 | 66 ± 15 | 31 ± 16 | pLVAD group: 75 Control group: 67 | Impella | pLVAD group: 30 control group: 31 | NA | 3 months |
| Lü et al., 2013[27] | 16 | No control group | 63 ± 11 | 20 ± 9 | ECMO: 60 Impella: 60 LVAD: 50 | ECMO: 5 patients Impella: 5 patients LVAD: 6 patients | 50 | 6 | 3 months |
| Miller et al., 2013[13] | 20 | Patients used as own controls | 59 ± 12 | 30 ± 7 | 50 | Impella 2.5 | 20 | 10 | 1 months |
| Aryana et al., 2014[17] | 68 | 34 | 66 ± 12 | 32 ± 10 | pLVAD group: 71 Control group: 71 | Impella 2.5/Impella CP | pLVAD group: 26 Control group: 41 | pLVAD group: 0 Control group: 6 | 19 ± 12 months |
| Reddy et al., 2014[16] | 44 | IABP: 22 | pLVAD group: 66 ± 12 Control group: 69 ± 10 | pLVAD group: 29 ± 15 Control group: 25 ± 10 | pLVAD group: 89 Control group: 86 | Impella: 25 TandemHeart: 19 | pLVAD group: 42 Control group: 50 | pLVAD group: 36 Control group: 36 | 12 ± 5 month |
| Baratto et al., 2016[25] | 64 | No control group | 63 ± 15 | 27 ± 9 | 69 | ECMO | 33 | 12 | Median: 21 months |
| Aryana et al., 2017[28] | 230 | IABP: 115 | NA | NA | NA | pLVAD not otherwise specified | Redo VT ablation: pLVAD group: 10.2 Control group: 14.0 | pLVAD group: 6.5 Control group: 19.1 | 12 months |
| Enriquez et al., 2017[19] | 21 | No control group | 60 ± 11 | 21 ± 13 | 83 | ECMO (rescue insertion due to AHD) | 30 | 76 | Median: 10 days |
| Kusa et al., 2017[18] | 109 | 85 | pLVAD group: 64 ± 11 Control group: 61 ± 15 | pLVAD group: 26 ± 10 Control group: 39 ± 16 | pLVAD group: 80 Control group: 93 | 80 with Impella 2.5 and 29 with Impella CP | pLVAD group: 32 Control group: 21 | pLVAD group: 12 Control group: 6 | Median: 215 days |
| Mathuria et al., 2017[10] | Rescue pLVAD:12 Pre-emptive pLVAD: 24 | 57 | Pre-emptive pLVAD group: 65.8 ± 14 control group: 64.8 ± 9 rescue pLVAD: 68.8 ± 8 | Pre-emptive pLVAD group: 26 ± 9 control group: 28 ± 5 rescue pLVAD: 24 ± 14 | Pre-emptive pLVAD group: 61 control group: 66 rescue pLVAD: 50 | Impella/TandemHeart | Pre-emptive pLVAD group: 4 Control group: 3.5 Rescue pLVAD: 58.3 | Pre-emptive pLVAD group: 26 Control group: 44 Rescue pLVAD: 40 | 3 months |
| Muser et al., 2018[20] | Pre-emptive pLVAD: 75 | 75 | pLVAD group: 65 ± 12 Control group: 64 ± 14 | pLVAD group: 27 ± 10 Control group: 27 ± 12 | pLVAD group: 81 Control group: 62 | Impella 2.5/Impella CP | pLVAD group: 33 Control group: 66 | pLVAD group: 40 Control group: 41 | 12 months |
ECMO: extra-corporeal membrane oxygenation; IABP: intra-aortic balloon pump; LVEF: left ventricular ejection fraction; pLVAD: percutaneous left ventricular assistance device; VT ventricular tachycardia.